Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | MC3R | P41968 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 2/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436016 | 0.91 | ADORA3 (0.46) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL27942339 | 0.84 | HDAC3 (0.42) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL1648472 | 0.82 | KDM4E (0.45) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL1532612 | 0.81 | HDAC3 (0.41) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL1483374 | 0.80 | ADORA3 (0.50) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL30373798 | 0.80 | ADORA3 (0.50) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL17675610 | 0.77 | PIM2 (0.42) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL24158585 | 0.77 | MEN1 (0.38) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL21740803 | 0.77 | KDM4E (0.41) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL21576120 | 0.77 | LMNA (0.39) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-2318402-A2 | PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS | Sanofi-aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010013078-A2 | PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2010-02-04 | — | — | WO | disclosed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-0369743-B1 | Heterocyclic amides | ZENECA LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| EP-0369743-A2 | Heterocyclic amides | ZENECA LIMITED (GB) | 1990-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174540-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | ADORA3 298/4885TSHR 3065/4885MC4R 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.